title: Translational approach to develop novel medications on alcohol addiction: focus on neuropeptides.
abstract: Research on alcohol and drug dependence has shown that the development of addiction depends on a complex interplay of psychological factors, genetic or epigenetic predisposing factors, and neurobiological adaptations induced by drug consumption. A greater understanding of the mechanisms leading to alcohol abuse will allow researchers to identify genetic variation that corresponds to a specific biological vulnerability to addiction, thus defining robust endophenotypes that might help deconstruct these complex syndromes into more tractable components. To this end, it is critical to develop a translational framework that links alterations at the molecular level, to changes in neuronal function, and ultimately to changes at the behavioral and clinical levels. Translational phenotypes can be identified by the combination of animal and human studies designed to elucidate the neurofunctional, anatomical and pharmacological mechanisms underlying the etiology of alcohol addiction. The present article offers an overview of medication development in alcoholism with a focus on the critical aspect of translational research. Moreover, significant examples of promising targets from neuropeptidergic systems, namely nociceptin/orphanin FQ and neuropeptide S are given.
authors: School of Pharmacy, Pharmacology Unit, University of Camerino, 62032, Camerino, Italy.
authors: Massimo
authors: M
authors: Ubaldi
authors: Angelo
authors: A
authors: Bifone
authors: Roberto
authors: R
authors: Ciccocioppo
mesh_terms: D000437:Alcoholism / Q000188:drug therapy*; D000818:Animals; D004353:Drug Evaluation, Preclinical; D006801:Humans; D009479:Neuropeptides / Q000627:therapeutic use*; D057170:Translational Research, Biomedical
chemical_list: D009479:Neuropeptides
references: Neuroscience. 2011 Jan 13;172:153-63
references: 20950671
references: Prog Neurobiol. 2013 Jan;100:48-59
references: 23041581
references: Psychopharmacology (Berl). 2002 Feb;159(4):415-23
references: 11823894
references: Br J Pharmacol. 2013 Feb;168(4):863-79
references: 22994368
references: Peptides. 2000 Jul;21(7):1125-30
references: 10998547
references: Psychopharmacology (Berl). 2008 Mar;196(4):523-31
references: 17989958
references: Biol Psychiatry. 2011 Apr 1;69(7):675-83
references: 21126735
references: Mol Pharmacol. 1999 Aug;56(2):334-8
references: 10419552
references: Neuroreport. 2000 Jun 26;11(9):1939-43
references: 10884047
references: Am J Psychiatry. 1994 Feb;151(2):178-83
references: 8296885
references: Biol Psychiatry. 2007 Jan 1;61(1):4-12
references: 16533497
references: Br J Pharmacol. 2005 Sep;146(1):33-40
references: 15980870
references: Peptides. 2002 Jan;23(1):117-25
references: 11814626
references: Neuron. 2004 Aug 19;43(4):487-97
references: 15312648
references: Pharmacol Biochem Behav. 2012 Dec;103(2):332-7
references: 22982682
references: Alcohol. 1986 Jan-Feb;3(1):39-54
references: 3964437
references: Psychopharmacology (Berl). 2005 Oct;182(1):132-43
references: 16025321
references: Alcohol. 1993 Jan-Feb;10(1):1-10
references: 8095393
references: Drug Alcohol Depend. 2013 Mar 1;128(3):175-86
references: 23294766
references: Alcohol Clin Exp Res. 2011 Apr;35(4):747-55
references: 21223310
references: Acta Psychiatr Belg. 1990 Jan-Feb;90(1):9-19
references: 1670391
references: J Comp Neurol. 2007 Jan 1;500(1):84-102
references: 17099900
references: J Med Chem. 2009 Jul 9;52(13):4068-71
references: 19473027
references: Neuropsychopharmacology. 2007 Apr;32(4):902-10
references: 16880770
references: Neuropsychopharmacology. 2009 Aug;34(9):2125-34
references: 19322167
references: Psychopharmacology (Berl). 2004 Mar;172(2):170-8
references: 14624331
references: Alcohol Clin Exp Res. 2002 Apr;26(4):558-64
references: 11981133
references: Am J Psychiatry. 2011 Feb;168(2):183-92
references: 21078704
references: Neuroscience. 1996 Nov;75(2):333-7
references: 8930999
references: Neuroimage. 2013 Apr 1;69:112-9
references: 23261637
references: J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):610-4
references: 17088334
references: Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15236-41
references: 17015825
references: Neuroimage. 2006 Sep;32(3):1465-71
references: 16872844
references: Psychopharmacology (Berl). 2013 Mar;226(2):347-55
references: 23149909
references: Bioorg Med Chem Lett. 2010 Aug 1;20(15):4704-8
references: 20615693
references: Peptides. 2009 Feb;30(2):234-40
references: 18992779
references: Science. 2012 Feb 3;335(6068):601-4
references: 22301321
references: Addict Biol. 2007 Mar;12(1):122-32
references: 17407506
references: Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19567-72
references: 20974945
references: J Pharmacol Exp Ther. 2008 Aug;326(2):672-82
references: 18492950
references: Eur J Pharmacol. 2000 Sep 15;404(1-2):153-9
references: 10980274
references: Behav Pharmacol. 2005 Mar;16(2):101-6
references: 15767845
references: Curr Top Behav Neurosci. 2013;13:543-82
references: 21590390
references: J Neurosci. 2003 Oct 15;23(28):9445-51
references: 14561874
references: Psychopharmacology (Berl). 1997 Jan;129(2):99-111
references: 9040115
references: J Neurosci. 2009 Apr 1;29(13):4155-61
references: 19339610
references: Brain. 2010 Apr;133(Pt 4):1043-53
references: 20133395
references: Alcohol Clin Exp Res. 2011 Sep;35(9):1678-85
references: 21599718
references: Neuropsychopharmacology. 2012 Oct;37(11):2436-45
references: 22739468
references: Pharmacol Ther. 2006 Sep;111(3):855-76
references: 16545872
references: Drug Alcohol Depend. 2009 Feb 1;100(1-2):17-23
references: 19026496
references: Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1867-72
references: 18801404
references: Alcohol Clin Exp Res. 2000 Jun;24(6):822-9
references: 10888070
references: Peptides. 2006 Dec;27(12):3299-306
references: 17097763
references: J Med Chem. 2011 Apr 28;54(8):2687-700
references: 21438532
references: J Subst Abuse Treat. 2008 Mar;34(2):215-23
references: 17596906
references: Eur J Pharmacol. 2011 Jul 1;661(1-3):63-71
references: 21545797
references: Lancet. 2003 Feb 22;361(9358):662-8
references: 12606177
references: J Med Chem. 1999 Dec 16;42(25):5061-3
references: 10602690
references: J Neurochem. 2010 Oct;115(2):475-82
references: 20722970
references: Neuroimage. 2010 Mar;50(1):267-76
references: 20004725
references: Psychopharmacology (Berl). 1999 Jan;141(2):220-4
references: 9952048
references: Peptides. 2010 May;31(5):926-31
references: 20156501
references: Eur J Pharmacol. 2010 Mar 25;630(1-3):112-20
references: 20006596
references: J Nucl Med. 2013 Mar;54(3):455-63
references: 23353688
references: Alcohol Clin Exp Res. 2010 Jan;34(1):90-7
references: 19860802
references: Alcohol Clin Exp Res. 2011 Oct;35(10):1771-93
references: 21777260
references: Alcohol Clin Exp Res. 1993 Oct;17(5):1040-3
references: 8279664
references: Eur J Pharmacol. 2009 Mar 15;606(1-3):84-9
references: 19374842
references: Pharmacol Ther. 2007 Nov;116(2):306-21
references: 17868902
references: Peptides. 2000 Jul;21(7):1141-6
references: 10998549
references: Alcohol Clin Exp Res. 2008 Aug;32(8):1380-7
references: 18564106
references: Peptides. 2010 Jun;31(6):1194-204
references: 20307605
references: J Comp Neurol. 2011 Jul 1;519(10):1847-66
references: 21452230
references: Addict Biol. 2006 Sep;11(3-4):339-55
references: 16961763
references: Brain Res. 1999 Jun 19;832(1-2):168-70
references: 10375664
references: Naunyn Schmiedebergs Arch Pharmacol. 2006 Feb;372(5):319-30
references: 16491387
references: Biol Psychiatry. 2008 Aug 1;64(3):211-8
references: 18367152
references: J Pharmacol Exp Ther. 2007 Jun;321(3):968-74
references: 17329551
references: Am J Psychiatry. 1992 Aug;149(8):1016-22
references: 1636801
references: J Pharmacol Exp Ther. 2003 Jan;304(1):310-8
references: 12490606
references: J Pharmacol Exp Ther. 2008 Jun;325(3):893-901
references: 18337476